


Targeting KRAS G12C:

A new era for patients
with advanced NSCLC

Wednesday 30 March 2022

11:30–13:00 CEST

SOUTH HALL 2



CHAIR

Professor Solange Peters
Lausanne, Switzerland



SPEAKER

Professor Keith Kerr
Aberdeen, Scotland, UK



SPEAKER

Dr Joop de Langen
Amsterdam, the Netherlands

AGENDA

- **Welcome and introduction**
Solange Peters
- **KRAS G12C inhibition: A major landmark in 2nd line treatment of patients with advanced NSCLC**
Joop de Langen
- **The turning point: Practical considerations when emerging biomarkers become actionable**
Keith Kerr
- **Forward thinking: Future perspectives in targeting KRAS in NSCLC**
Solange Peters
- **Panel discussion**
All
- **Audience Q&A**
All (moderated by Solange Peters)
- **Summary and close**
Solange Peters

AMGEN
Oncology

SC-ELMAC-AMG 510-00042
Date of preparation: March 2022
Amgen (Europe) GmbH, 6343 Rotkreuz, Switzerland
© 2022 Amgen Inc. All rights reserved.